Inland Peptides

Research guide

What Is CBL-514, and How Does It Compare With Weight-Loss Peptides?

November 4, 2026

CBL-514 is an experimental drug studied for reducing fat beneath the skin in a specific area, such as the abdomen.

It is a small-molecule drug developed by Caliway Biopharmaceuticals in Taiwan. Unlike peptide medicines such as semaglutide and tirzepatide, CBL-514 is not made from a chain of amino acids.

How is CBL-514 thought to work?

Caliway says CBL-514 triggers apoptosis, or programmed cell death, in fat cells. This is a normal process the body uses to remove cells.

The proposed mechanism comes from unpublished company laboratory and animal research cited in the study papers. Human scans have shown less fat after treatment, but they cannot confirm that fat cells died.

How is local fat reduction different from weight loss?

Local fat reduction means losing fat in one part of the body. Weight loss means a drop in total body weight.

Losing 20% of the fat in one treated area is different from losing 20% of total body weight. A smaller amount of abdominal fat may change the shape of the belly without much change on the scale.

The published abdominal CBL-514 studies measured fat volume or thickness with ultrasound or MRI scans. Participants were asked to keep their weight steady. Weight-loss drug studies measure changes in total body weight over many months.

How does CBL-514 compare with weight-loss peptides?

CBL-514 is being studied for reducing fat in a treated area. The peptides below act on hormone receptors involved in appetite, blood sugar and metabolism.

GLP-1, GIP and glucagon are hormones made in the gut or pancreas. Amylin is another pancreatic hormone that helps people feel full after a meal.

Receptors are proteins that receive signals from hormones. An agonist activates a receptor. These peptide drugs mimic one or more of those hormone signals.

The studies summarized here did not directly compare CBL-514 with any of these peptide drugs.

Compound What it is General action Studied for Development and approval history
CBL-514 Nonpeptide small molecule Proposed to trigger programmed death of fat cells Fat in a treated area; lipomas in Dercum disease Investigational; Phase 3 study began in 2026
Semaglutide Peptide GLP-1 receptor agonist Blood sugar; body weight FDA: Ozempic (2017), type 2 diabetes; Wegovy (2021), weight management
Tirzepatide Peptide GIP and GLP-1 receptor agonist Blood sugar; body weight FDA: Mounjaro (2022), type 2 diabetes; Zepbound (2023), weight management
Retatrutide Peptide GIP, GLP-1 and glucagon receptor agonist Body weight; blood sugar Studied as an investigational treatment
Mazdutide Peptide GLP-1 and glucagon receptor agonist Body weight; blood sugar China: approved for adult weight management (2025)
Survodutide Peptide GLP-1 and glucagon receptor agonist Body weight; fatty liver disease Studied as an investigational treatment
Pemvidutide Peptide GLP-1 and glucagon receptor agonist Fatty liver disease; body weight Studied as an investigational treatment
Cagrilintide Peptide modeled on amylin Amylin receptor agonist Body weight Studied as an investigational treatment
CagriSema Cagrilintide plus semaglutide Amylin and GLP-1 receptor agonists together Body weight; blood sugar Studied as an investigational treatment
Pramlintide Peptide modeled on amylin Amylin receptor agonist Blood sugar after meals FDA: Symlin (2005), diabetes with mealtime insulin; not a weight-loss approval

What have human studies found?

Three published studies found that CBL-514 reduced fat in the treated part of the abdomen.

A small early study enrolled 43 adults and had no placebo group. Among participants who completed the study as planned, the highest-dose group had about 25% less fat in the treated area four weeks after the last treatment.

A placebo-controlled study enrolled 76 adults. At eight weeks after the last treatment, 16 of the 23 CBL-514 participants with measurements had lost at least 150 mL of fat in the treated area, compared with none of the 16 measured on placebo. Participants did not know which treatment they received, but the investigators did.

A larger study published in 2026 randomly assigned 108 adults to CBL-514 or placebo. MRI scans showed a greater drop in abdominal fat with CBL-514. Participants and clinicians also reported more improvement, though the clinicians knew which treatment people received.

These studies were designed to measure local fat reduction, not weight loss.

Side effects were mostly injection-site pain, redness, swelling, itching and bruising. Some participants had severe pain or stopped treatment because of side effects. Raised cholesterol or triglycerides were also reported. The cause was uncertain in some cases; in the 76-person study, one event was judged probably treatment-related.

Follow-up in these abdominal studies lasted no more than 12 weeks after the last treatment. Many participants left early, including nearly half in the 76-person study. Missing results make it harder to judge how well the treatment worked across everyone enrolled.

Caliway funded the studies. Authors included company employees, shareholders and paid consultants.

Dercum disease

CBL-514 has also been studied in Dercum disease, a rare condition that causes painful fatty lumps called lipomas.

In a published study of 12 adults with no placebo group, treated lipomas typically shrank by roughly half over four to eight weeks, and pain scores fell. Four participants had severe side effects, and two stopped treatment. Caliway funded this study too, and company employees were among the authors.

In September 2026, Caliway announced results from a later placebo-controlled study of 19 people. It reported a greater drop in pain with CBL-514 than with placebo. This was a company announcement, rather than a peer-reviewed journal report.

What combination research has been reported?

Caliway has reported animal studies combining CBL-514 with semaglutide, tirzepatide or eloralintide, an experimental drug that mimics amylin. The findings were described in company announcements and conference presentations.

The company reported more weight loss and less regain after treatment stopped in animals given CBL-514 with semaglutide or tirzepatide. A September 2026 announcement described similar findings with semaglutide or eloralintide.

These announcements did not report human combination results or provide peer-reviewed papers. The animal findings do not establish benefits in people.

In August 2026, Caliway announced that the FDA had cleared a Phase 2 trial of CBL-514 with tirzepatide in adults with overweight or obesity. Trial clearance permits research; it is not approval to market a treatment.

Has CBL-514 been studied for visceral fat?

Yes. Caliway reported an exploratory analysis of visceral fat, the fat around internal organs, in participants from two abdominal studies. This is deeper than the fat beneath the skin.

In the MRI analysis, visceral fat volume fell with CBL-514 and rose with placebo. About 40 participants had follow-up measurements. The findings were presented at a 2026 medical meeting and reported by Caliway. This small subgroup analysis does not establish weight loss or other health benefits.

What CBL-514 trials measured: fat in a treated abdominal area, versus weight-loss trials that measure total body weight.
The abdominal trials measured fat in a treated area. Weight-loss trials measure changes in total body weight.